Paul Pollack

2.3k total citations · 1 hit paper
29 papers, 1.7k citations indexed

About

Paul Pollack is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Paul Pollack has authored 29 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 17 papers in Epidemiology and 12 papers in Surgery. Recurrent topics in Paul Pollack's work include Inflammatory Bowel Disease (22 papers), Microscopic Colitis (14 papers) and Eosinophilic Esophagitis (6 papers). Paul Pollack is often cited by papers focused on Inflammatory Bowel Disease (22 papers), Microscopic Colitis (14 papers) and Eosinophilic Esophagitis (6 papers). Paul Pollack collaborates with scholars based in United States, Belgium and Canada. Paul Pollack's co-authors include William J. Sandborn, Paul Rutgeerts, Douglas C. Wolf, Donald MacIntosh, Milan Lukáš, Remo Panaccione, Richard N. Fedorak, Stephen B. Hanauer, Daphne Chan and Brian G. Feagan and has published in prestigious journals such as Gastroenterology, Journal of Nutrition and The American Journal of Gastroenterology.

In The Last Decade

Paul Pollack

27 papers receiving 1.7k citations

Hit Papers

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Ada... 2006 2026 2012 2019 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
    2006 1.3k citations Stephen B. Hanauer, William J. Sandborn et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Pollack United States 10 1.4k 1.1k 490 440 168 29 1.7k
D. H. Present United States 6 1.4k 1.0× 1.1k 1.0× 236 0.5× 505 1.1× 96 0.6× 11 1.7k
Benjamin Pariente France 23 1.4k 1.0× 1.1k 1.0× 420 0.9× 665 1.5× 67 0.4× 88 1.8k
S Stoĭnov Belgium 5 768 0.6× 587 0.5× 261 0.5× 242 0.6× 357 2.1× 8 1.2k
Michael Smyth United Kingdom 14 816 0.6× 650 0.6× 261 0.5× 256 0.6× 50 0.3× 43 1.1k
Sara Onali Italy 26 1.1k 0.8× 709 0.6× 269 0.5× 514 1.2× 73 0.4× 68 1.5k
Judith Collins United States 9 1.3k 0.9× 1.0k 0.9× 357 0.7× 354 0.8× 103 0.6× 18 1.7k
Pavol Papay Austria 15 632 0.5× 576 0.5× 311 0.6× 323 0.7× 99 0.6× 37 1.2k
Yinghua Lang United States 9 1.2k 0.9× 974 0.9× 303 0.6× 431 1.0× 91 0.5× 15 1.4k
Yulia Ron Israel 14 793 0.6× 600 0.5× 411 0.8× 273 0.6× 42 0.3× 47 1.1k
Satoru Umegae Japan 23 1.2k 0.9× 930 0.9× 197 0.4× 658 1.5× 47 0.3× 53 1.5k

Countries citing papers authored by Paul Pollack

Since Specialization
Citations

This map shows the geographic impact of Paul Pollack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Pollack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Pollack more than expected).

Fields of papers citing papers by Paul Pollack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Pollack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Pollack. The network helps show where Paul Pollack may publish in the future.

Co-authorship network of co-authors of Paul Pollack

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Pollack. A scholar is included among the top collaborators of Paul Pollack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Pollack. Paul Pollack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Magro, Fernando, Marijana Protić, Gert De Hertogh, et al.. (2023). Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial. Clinical Gastroenterology and Hepatology. 22(9). 1878–1888.e10. 7 indexed citations
2.
Pollack, Paul, et al.. (2023). On Benford’s law for multiplicative functions. Proceedings of the American Mathematical Society. 151(11). 4607–4619.
3.
Regueiro, Miguel, Monika Fischer, David T. Rubin, et al.. (2022). S834 Improvement in Fatigue With Mirikizumab Therapy Is Associated With Clinical Remission and Pain Improvements but Not With Endoscopic Response in Patients With Moderately-to-Severely Active Crohn’s Disease. The American Journal of Gastroenterology. 117(10S). e602–e603. 1 indexed citations
4.
Sandborn, William J., Bruce E. Sands, Monika Fischer, et al.. (2020). S0705 Evaluation of Symptom Improvement During Induction in Patients With Crohn's Disease Treated With Mirikizumab. The American Journal of Gastroenterology. 115(1). S354–S354. 4 indexed citations
5.
Sands, Bruce E., William J. Sandborn, Laurent Peyrin‐Biroulet, et al.. (2019). 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease. Gastroenterology. 156(6). S–216. 19 indexed citations
6.
Li, Katherine, Joshua R. Friedman, Daphne Chan, et al.. (2019). Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease. Gastroenterology. 157(4). 1019–1031.e7. 48 indexed citations
7.
Rutgeerts, Paul, Christopher Gasink, Daphne Chan, et al.. (2018). Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease. Gastroenterology. 155(4). 1045–1058. 115 indexed citations
8.
Sandborn, William J., C Gasink, Daphne Chan, et al.. (2016). Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award. The American Journal of Gastroenterology. 111. S278–S279. 2 indexed citations
9.
Al‐Alaiyan, Saleh, Paul Pollack, & Gerard Notario. (2015). Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs in Context. 4. 1–10. 6 indexed citations
10.
11.
12.
Colombel, Jean–Frédéric, Édouard Louis, Remo Panaccione, et al.. (2012). Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE. Inflammatory Bowel Diseases. 18. S39–S39. 2 indexed citations
13.
14.
Colombel, Jean–Frédéric, Paul Rutgeerts, William J. Sandborn, et al.. (2010). Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND. The American Journal of Gastroenterology. 105. S434–S435. 10 indexed citations
15.
Colombel, J F, Michael A. Kamm, David A. Schwartz, et al.. (2008). Long-Term Adalimumab Treatment Is Associated with Sustained Fistula Healing in Patients with Moderate to Severe Crohnʼs Disease. The American Journal of Gastroenterology. 103. S417–S417. 2 indexed citations
16.
Hanauer, Stephen B., William J. Sandborn, Paul Rutgeerts, et al.. (2006). Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial. Gastroenterology. 130(2). 323–333. 1277 indexed citations breakdown →
17.
18.
19.
Buchman, Alan L., Adib Moukarzel, Paul Pollack, et al.. (1994). Catheter‐Related Infections Associated With Home Parenteral Nutrition and Predictive Factors for the Need for Catheter Removal in Their Treatment. Journal of Parenteral and Enteral Nutrition. 18(4). 297–302. 96 indexed citations
20.
Thornburg, William, et al.. (1987). Response of Activity of Jejunal Disaccharidases and Pancreatic Amylase in Young and Middle-Aged Rats to a High Carbohydrate Diet. Journal of Nutrition. 117(1). 63–69. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. H. Present Breakdown of academic impact, for papers by Benjamin Pariente Breakdown of academic impact, for papers by S Stoĭnov Breakdown of academic impact, for papers by Michael Smyth Breakdown of academic impact, for papers by Sara Onali Breakdown of academic impact, for papers by Judith Collins Breakdown of academic impact, for papers by Pavol Papay Breakdown of academic impact, for papers by Yinghua Lang Breakdown of academic impact, for papers by Yulia Ron Breakdown of academic impact, for papers by Satoru Umegae
Rankless by CCL
2026